Greg Folkers
Washington, D.C.
- The Atlantic: The Only Thing That Will Turn Measles Back / A rebound in vaccination—which may depend on government support by Katherine J. Wu @theatlantic.com bit.ly/3ZQl407
- Sci Transl Med: Phase 1 and preclinical studies reveal safety, pharmacokinetics, and efficacy of intranasal delivery of the influenza antibody CR9114 Anna L Beukenhorst et al bit.ly/4ajUBwV
- Bulwark podcast: RFK Jr. Is Letting Measles Come Back bit.ly/4a0labG @samsteindc.bsky.social @citizencohn.bsky.social
- CIDRAP: 2024-25 COVID vaccine 80% effective against death, CDC estimates bit.ly/4r2OrIP @cidrap.bsky.social
- Nature Immunology: Better and closer glycan-independent anti-V3 antibodies to help HIV-1 vaccine by Julià Blanco go.nature.com/4knXX6U
- The New World: The slow death of American science by Philip Ball NIH Jay Bhattahcrya bit.ly/4keFysW
- Undark: Kyle Walsh’s appointment to head the NIEHS, a $914-million public agency, is unprecedented. What is on his agenda? By Michael Schulson @undark.org NIH Jay Bhattacharya bit.ly/4rq9l4g
- Beyond the Noise #92: RFK Jr.’s Strategy for Restoring Trust / Paul Offit @pauloffit.bsky.social bit.ly/46ibxTe
- Nature Med: Global and regional cancer burden attributable to modifiable risk factors to inform prevention Hanna Fink et al go.nature.com/3ZOoLn7
- ScienceInsider: Senate panel slams Trump’s NIH chief for grant cuts, vaccine views Jay Bhattacharya By Jocelyn Kaiser @jocelynkaiser.bsky.social @science.org bit.ly/4a7UC6Z
